TMPRSS2 and COVID-19: The highlights of the present study contribute to the knowledge of the specific polymorphisms that could affect COVID-19 severity through the identification of new pharmacological targets and treatment strategies to block SARS-CoV-2 entry via TMPRSS2 inhibition, such as argatroban and famotidine, which act as new scaffolds for TMPRSS2 inhibition (62), and other future treatments that could be used for other similar diseases.